 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- SUCCESSFUL TREATMENT OF REFRACTORY COVID19 WITH (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1466;
Patient 1
- | ALVR109 / AlloVir
Journal: Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients. (Pubmed Central) - Nov 15, 2022
P1
The feasibility of making and safely utilizing such VSTs clinically was assessed by administering partially HLAmatched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109) in combination with other antiviral agents to 4 individuals who were hospitalized with COVID-19. In conclusion, this study establishes the feasibility of preparing and delivering off-the-shelf SARS-CoV-2-directed VSTs to patients with COVID-19 and supports the clinical use of VSTs outside of the profoundly immune compromised setting (ClinicalTrials.gov number, NCT04401410).
- ALVR109 / AlloVir
Early Clinical Experience With Alvr109, A Partially Hla-matched Sars-cov-2 Specific T-cell Therapy, In Immunocompromised Patients With Covid-19 (Hynes Room 310) - May 20, 2022 - Abstract #ATC2022ATC_2030;
SARS-CoV-2-specific T-cells appear to be safe and may control viremia in IC pts. Larger studies are needed to confirm this observation, define the best candidates for ALVR109, and determine optimal timing of administration.
- |||| ALVR109 / AlloVir
#ASH20 Wow! What a brilliant, novel talk by Dr S. Vasileiou PhD 👉Using allogeneic off the shelf SARS-CoV-2-specific T cells to treat High risk patients with #COVID19 | Based on this pre-clinical data, now has moved to clinical trial #ALVR109 with study design below. #ASHKudos (Twitter) - Dec 7, 2020